Rasagiline
Rasagiline is an irreversible monoamine oxidase (MAO) inhibitor that is thought to exert its effect by specifically inhibiting MAO-B, thereby causing an increase in the extracellular levels of dopamine in the striatum.
TEVA
First once-daily oral treatment for Parkinson's disease approved
Rasagiline is an irreversible monoamine oxidase (MAO) inhibitor that is thought to exert its effect by specifically inhibiting MAO-B, thereby causing an increase in the extracellular levels of dopamine in the striatum. Rasagiline was approved on May 16, 2005, for the treatment of the signs and symptoms of idiopathic Parkinson's disease (PD) as initial monotherapy and as adjunct therapy to levodopa.
Safety. Rasagiline is contraindicated for use with the analgesics meperidine, tramadol, methadone, and propoxyphene. Patients taking rasagiline should not take dextromethorphan or sympathomimetic amines such as pseudoephedrine and phenylephrine. Rasagiline should not be administered along with other MAO inhibitors due to the increased risk of non-selective MAO inhibition that may lead to hypertensive crisis. The coadministration of rasagiline with selective serotonin reuptake inhibitors (SSRIs), tricyclic antidepressants, or tetracyclic antidepressants is not recommended. Patients taking rasagiline should not undergo elective surgery requiring general anesthesia, and the agent should be discontinued at least 14 days prior to elective surgery because of hypertension concerns. Due to the risk of a hypertensive crisis/"cheese reaction," a dietary tyramine restriction is necessary in patients currently taking rasagiline and for 2 weeks following discontinuation of the drug. The most common adverse events associated with rasagiline monotherapy include flu syndrome, arthralgia, depression, dyspepsia, and fall.
Dosing. The recommended dose of rasagiline as monotherapy is 1.0 mg administered once daily. The recommended initial dose of rasagiline as adjunct therapy to levodopa is 0.5 mg administered once daily. If a sufficient clinical response is not achieved with 0.5 mg, the dose may be increased to 1.0 mg administered once daily. When rasagiline is administered in combination with levodopa, a reduction of the levodopa dose may be considered based upon individual response. The rasagiline dose should be reduced to 0.5 mg daily in patients taking ciprofloxacin and other CYP1A2 inhibitors. Patients with mild hepatic impairment should take 0.5 mg of rasagiline daily. Patients with moderate-to-severe hepatic impairment should not take rasagiline.
Coalition promotes important acetaminophen dosing reminders
November 18th 2014It may come as a surprise that each year Americans catch approximately 1 billion colds, and the Centers for Disease Control and Prevention estimates that as many as 20% get the flu. This cold and flu season, 7 in 10 patients will reach for an over-the-counter (OTC) medicine to treat their coughs, stuffy noses, and sniffles. It’s an important time of the year to remind patients to double check their medicine labels so they don’t double up on medicines containing acetaminophen.
Support consumer access to specialty medications through value-based insurance design
June 30th 2014The driving force behind consumer cost-sharing provisions for specialty medications is the acquisition cost and not clinical value. This appears to be true for almost all public and private health plans, says a new report from researchers at the University of Michigan Center for Value-Based Insurance Design (V-BID Center) and the National Pharmaceutical Council (NPC).
Management of antipsychotic medication polypharmacy
June 13th 2013Within our healthcare-driven society, the increase in the identification and diagnosis of mental illnesses has led to a proportional increase in the prescribing of psychotropic medications. The prevalence of mental illnesses and subsequent treatment approaches may employ monotherapy as first-line treatment, but in many cases the use of combination of therapy can occur, leading to polypharmacy.1 Polypharmacy can be defined in several ways but it generally recognized as the use of multiple medications by one patient and the most common definition is the concurrent use of five more medications. The presence of polyharmacy has the potential to contribute to non-compliance, drug-drug interactions, medication errors, adverse events, or poor quality of life.
Medical innovation improves outcomes
June 12th 2013I have been diagnosed with stage 4 cancer of the pancreas, a disease that’s long been considered not just incurable, but almost impossible to treat-a recalcitrant disease that some practitioners feel has given oncology a bad name. I was told my life would be measured in weeks.
